Stempoint Capital LP Buys Shares of 1,594,491 Biohaven Ltd. $BHVN

Stempoint Capital LP purchased a new position in shares of Biohaven Ltd. (NYSE:BHVN) during the 1st quarter, HoldingsChannel.com reports. The fund purchased 1,594,491 shares of the company’s stock, valued at approximately $13,489,000. Biohaven comprises 2.6% of Stempoint Capital LP’s holdings, making the stock its 12th biggest position.

Other institutional investors and hedge funds have also recently modified their holdings of the company. AQR Capital Management LLC raised its stake in Biohaven by 49.4% during the first quarter. AQR Capital Management LLC now owns 114,849 shares of the company’s stock worth $2,761,000 after purchasing an additional 37,981 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Biohaven by 32.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,833 shares of the company’s stock valued at $1,747,000 after purchasing an additional 17,562 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Biohaven by 7.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 589,615 shares of the company’s stock valued at $14,174,000 after buying an additional 41,040 shares during the period. Intech Investment Management LLC grew its stake in shares of Biohaven by 80.3% in the 1st quarter. Intech Investment Management LLC now owns 61,598 shares of the company’s stock valued at $1,481,000 after buying an additional 27,433 shares during the period. Finally, Quantbot Technologies LP increased its holdings in shares of Biohaven by 1,097.8% during the 2nd quarter. Quantbot Technologies LP now owns 8,840 shares of the company’s stock worth $125,000 after buying an additional 8,102 shares during the last quarter. Institutional investors and hedge funds own 88.78% of the company’s stock.

Biohaven Price Performance

BHVN stock opened at $13.42 on Thursday. The company has a current ratio of 7.41, a quick ratio of 7.41 and a debt-to-equity ratio of 1.87. The company has a market capitalization of $2.02 billion, a PE ratio of -2.37 and a beta of 1.28. Biohaven Ltd. has a 12-month low of $7.48 and a 12-month high of $18.57. The business’s fifty day moving average price is $13.43 and its 200 day moving average price is $11.53.

Biohaven (NYSE:BHVN) last announced its earnings results on Monday, May 4th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). On average, sell-side analysts anticipate that Biohaven Ltd. will post -3.1 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Citigroup increased their price objective on Biohaven from $14.00 to $17.00 and gave the stock a “buy” rating in a research report on Thursday, April 2nd. HC Wainwright reiterated a “neutral” rating and set a $10.00 price target on shares of Biohaven in a report on Tuesday, May 26th. Raymond James Financial reissued a “strong-buy” rating on shares of Biohaven in a research report on Wednesday, May 27th. Needham & Company LLC set a $11.00 price objective on shares of Biohaven in a report on Monday, June 29th. Finally, Canaccord Genuity Group assumed coverage on shares of Biohaven in a research report on Monday, April 13th. They issued a “buy” rating and a $21.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $21.62.

About Biohaven

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.